Technical Analysis for RNN - Rexahn Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.53 -2.91% -0.02
RNN closed down 2.91 percent on Friday, March 22, 2019, on 19 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RNN trend table...

Date Alert Name Type % Chg
Mar 22 20 DMA Resistance Bearish 0.00%
Mar 21 Fell Below 20 DMA Bearish -2.91%
Mar 21 180 Bearish Setup Bearish Swing Setup -2.91%
Mar 21 Narrow Range Bar Range Contraction -2.91%
Mar 21 NR7 Range Contraction -2.91%
Mar 21 NR7-2 Range Contraction -2.91%
Mar 20 Crossed Above 20 DMA Bullish -5.36%
Mar 20 Narrow Range Bar Range Contraction -5.36%
Mar 20 NR7 Range Contraction -5.36%
Mar 19 Fell Below 20 DMA Bearish -3.46%

Older signals for RNN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt-1, which has completed a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as is focusing on initiating Phase IIa clinical trials for chemo-resistant solid tumors and hematological malignancies; RX-3117, which has completed an exploratory Phase I clinical study in humans with therapeutic potential in a range of cancers, including colon, lung, and pancreatic cancer; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase and focuses on initiating Phase I clinical trials. The company's pre-clinical pipeline consist of RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, nano-polymer anticancer. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Cancer Alpha Cancers Pancreatic Cancer Central Nervous System Disorders Hematological Malignancies Treatment Of Pancreatic Cancer Chemo Protein Kinase B Sexual Dysfunction
Is RNN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.38
52 Week Low 0.5
Average Volume 1,123,252
200-Day Moving Average 1.2416
50-Day Moving Average 0.6733
20-Day Moving Average 0.5486
10-Day Moving Average 0.559
Average True Range 0.0405
ADX 9.24
+DI 14.9655
-DI 20.2724
Chandelier Exit (Long, 3 ATRs ) 0.4985
Chandelier Exit (Short, 3 ATRs ) 0.6215
Upper Bollinger Band 0.5861
Lower Bollinger Band 0.5111
Percent B (%b) 0.25
BandWidth 13.671163
MACD Line -0.0261
MACD Signal Line -0.0339
MACD Histogram 0.0079
Fundamentals Value
Market Cap 15.08 Million
Num Shares 28.5 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -0.52
Price-to-Sales 0.00
Price-to-Book 3.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.58
Resistance 3 (R3) 0.58 0.56 0.57
Resistance 2 (R2) 0.56 0.55 0.56 0.56
Resistance 1 (R1) 0.55 0.54 0.54 0.55 0.56
Pivot Point 0.53 0.53 0.53 0.53 0.53
Support 1 (S1) 0.52 0.52 0.51 0.52 0.50
Support 2 (S2) 0.50 0.51 0.50 0.50
Support 3 (S3) 0.49 0.50 0.49
Support 4 (S4) 0.49